McKesson | Strategic Alliance Partnership

In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.

In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.

In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.

“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

Interview on Ontada research presented at ISPOR 2024.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

While the novel payment models for expensive cell and gene therapies have been effective, they need to continue evolving, said Joe DePinto, MBA, of McKesson.

"The government really didn't rise to the challenge the way that it should have,” notes Ben Jones, vice president of government relations and public policy for The US Oncology Network. “Practices were in distress…stretching all resources to figure out workarounds."

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Coverage from the June 8, 2023, Institute for Value-Based Medicine session in Austin, Texas, held in partnership with Texas Oncology.

Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

In a statement, The US Oncology Network said the addition expands its reach into Kansas, continues pattern of strong growth in 2023.

While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.